Literature DB >> 33422366

Status of Metastatic Bladder Cancer Treatment Illustrated by a Case.

Line Hammer Dohn1, Lise Høj Omland2, Dag Rune Stormoen2, Helle Pappot3.   

Abstract

OBJECTIVE: This study aims to provide an overview of current treatment guidelines within the context of metastatic bladder cancer illustrated by a case report. DATA SOURCES: International guidelines from The American Society of Clinical Oncology (ASCO), The European Society of Medical Oncology (ESMO), and scientific references supporting these clinical guidelines. To illustrate the implementation of current evidence-based guidelines a patient case report was presented.
CONCLUSION: Historically, there have been limited treatment options available for metastatic bladder cancer for three decades. However, with the introduction of immunotherapy and emergent targeted therapies for metastatic bladder cancer increasing survival rates are expected. IMPLICATIONS FOR NURSING PRACTICE: To achieve improved treatment outcome in people affected by metastatic bladder cancer it is important that both doctors and nurses are aware of contemporary evidence-based treatment options in keeping with ESMO and ASCO international clinical guidelines. Nurses play an important role in educating patients about the potential side effects of therapy and in offering timely, tailored, and supported self-management.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Guidelines; Treatment

Year:  2021        PMID: 33422366     DOI: 10.1016/j.soncn.2020.151113

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  1 in total

1.  PD-L1 expression and FGFR-mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study.

Authors:  Trine Grantzau; Birgitte Grønkaer Toft; Linea Cecilie Melchior; Johanna Elversang; Dag Rune Stormoen; Lise Høj Omland; Helle Pappot
Journal:  APMIS       Date:  2022-06-15       Impact factor: 3.428

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.